OMED Key Stats
|Revenue (Quarterly YoY Growth)||67.02%|
|EPS Diluted (TTM)||-9.420|
|EPS Diluted (Quarterly YoY Growth)|
|Net Income (TTM)||-26.02M|
|Gross Profit Margin (Quarterly)|
|Profit Margin (Quarterly)||-26.96%|
|Dividend Yield (TTM)||0%|
|Payout Ratio (TTM) Pro||Go Pro|
- Who Benefits From the OncoMed and Celgene Partnership? Fool Dec 4
- OncoMed (OMED) Initiates OMP-18R5 + Abraxane Phase 1b Street Insider Dec 4
- Pre-Open Stock Movers 12/04: (OCLS) (PLUG) (OMED) Higher; (AMBI) (EXPR) (OVTI) Lower (more...) Street Insider Dec 4
- OncoMed (OMED) Target Lifted to $46 at Jefferies after Celgene Deal Street Insider Dec 4
- Holidays Came Early This Year for OncoMed and EnteroMedic The Street Dec 4
- Why OncoMed Pharmaceuticals, Unilife, and Tesla Motors Are Today's 3 Best Stocks Fool Dec 3
- Notable 52-Week Highs and Lows of the Day 12/03: (UNIS) (MDLZ) (OMED) High; (FIO) (CIE) Low Street Insider Dec 3
- Why OncoMed Pharmaceuticals Inc. Shares More Than Doubled Fool Dec 3
- Unusual 11 Mid-Day Movers 12/03: (OMED) (ETRM) (REX) Higher; (KKD) (ECTE) (YRCW) Lower Street Insider Dec 3
- Celgene (CELG) Invests Potentially Billions in OncoMed's (OMED) Technology that Targets Cancer Stem Cells Street Insider Dec 3
OMED Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). OncoMed Pharmaceuticals is up N/A over the last year vs S&P 500 Total Return up 29.68%, Actelion up 63.10%, and Agios Pharmaceuticals up N/A.
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Income Statement View Statement
Balance Sheet View Statement
Pro Ratings for OMED
Pro Report PDF for OMED
Download Pro Ratings, Key Stats, Performance Charts, Valuations, and Financials in an easy to print format.Download OMED Pro Report PDF
Pro Strategies Featuring OMED
Did OncoMed Pharmaceuticals make it into our Pro Portfolio Strategies?
Start your YCharts Pro membership now to find out.
OncoMed Pharmaceuticals Inc is engaged in the development of monoclonal antibody drugs that target cancer stem cells. The Company has five product candidates in clinical development.